Pulse Biosciences Inc
NASDAQ:PLSE
| Market Cap (Intraday) | 939.37M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $15.08 |
| 50-Day MA | $15.48 |
| 200-Day MA | $17.18 |
Pulse Biosciences Inc Stock, NASDAQ:PLSE
3957 Point Eden Way, 3957 Point Eden Way, Hayward, California 94545
United States of America
Phone: +1.510.906.4600
Number of Employees: 56
Description
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.